Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

BACKGROUND: Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimi-dine, oxaliplatin and irinotecan; novel agents need to be explored in this setting. Dasatinib, an oral inhibitor of Src family kinases, inhibits proliferation in CRC cell lines and has antitumor act...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Sharma, Manish R., Wroblewski, Kristen, Polite, Blase N., Knost, James A., Wallace, James A., Modi, Sanjiv, Sleckman, Bethany G., Taber, David, Vokes, Everett E., Stadler, Walter M., Kindler, Hedy L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317401/
https://ncbi.nlm.nih.gov/pubmed/21552992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9681-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia